

PRESS RELEASE

Lund, Sweden, January 25, 2024

The rights issue and the directed share issue to certain guarantors in Spago Nanomedical fully registered

The rights issue and the directed share issue to certain guarantors in Spago Nanomedical AB (publ) ("Spago Nanomedical" or the "Company") have now been fully registered with the Swedish Companies Registration Office.

As communicated by the Company through previous press releases in December, certain guarantors in the rights issue were, due to regulatory reasons, prohibited from receiving shares in the rights issue and the subsequent directed share issue without first obtaining approval from the Inspectorate of Strategic Products (Sw: Inspektionen för strategiska produkter, "ISP"). Approval was obtained by ISP in January 2024 and the issues have consequently been completed and registered with the Swedish Companies Registration Office.

Following the final registration of the rights issue and the directed share issue, the Company's share capital amounts to 22,471,545.40 SEK and the total number of shares to 224,715,454.

Advisors

Redeye AB acts as financial advisor, and Advokatfirman Cederquist KB acts as legal advisor to Spago Nanomedical in connection with the rights issue.

For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se

Spago Nanomedical AB is a Swedish company in clinical development phase. The company's development projects are based on a platform of polymeric materials with unique properties for more precise treatment and diagnosis of cancer and other debilitating diseases. Spago Nanomedical's share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.

FNCA Sweden AB is the Certified Adviser of the company.

The rights issue and the directed share issue to certain guarantors in Spago Nanomedical fully registered